TTrialPathMatch Me to Trials
← Back to trials
RecruitingAcute Myeloid Leukemia (AML)

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Eligible age

18+ yrs

Accepts

All genders

Locations

25 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells. This protocol has 2 separate studies that will investigate the benefits and risks of adding ziftomenib to standard-of-care (SOC) AML treatments in patients with certain genetic mutations who have not received any treatment for their AML. In the first study, the Nonintensive Therapy Study, older patients or those with serious medical problems will receive the SOC therapies venetoclax (ven) and azacitidine (aza), plus either ziftomenib or a placebo. In the second study, the Intensive Therapy Study, medically fit patients will receive (a) the SOC therapies cytarabine and daunorubicin, plus either ziftomenib or a placebo during a first treatment phase called induction, (b) cytarabine plus either ziftomenib or a placebo during a second treatment phase called consolidation, and (c) ziftomenib or a placebo during a third treatment phase called maintenance. The physician will determine which study is the appropriate treatment for the patient, but neither the patient nor their physician will know whether the patient has been assigned to receive ziftomenib or a placebo. This design is called "double-blinded".

Sponsor: Kura Oncology, Inc.

Where it's recruiting

Arizona

Gilbert

California

Clovis · La Jolla · Los Angeles · Orange

Colorado

Aurora · Denver

Connecticut

Hartford · New Haven

Florida

Miami · Tampa

Illinois

Chicago

Iowa

Iowa City

Kansas

Fairway

Kentucky

Lexington

Massachusetts

Boston · Worcester

Michigan

Ann Arbor · Detroit

Minnesota

Minneapolis · Saint Paul

Source: ClinicalTrials.gov · NCT07007312 · last updated 2026-11-12

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Pat · TrialPath